a4b7 Integrin in Eosinophilic Esophagitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02546219|
Recruitment Status : Active, not recruiting
First Posted : September 10, 2015
Last Update Posted : April 6, 2018
|Condition or disease||Intervention/treatment|
|Eosinophilic Esophagitis||Other: Eosinophil isolation and characterization.|
|Study Type :||Observational|
|Estimated Enrollment :||16 participants|
|Official Title:||Investigating the Role of a4b7 Integrin as a Therapeutic Target in Eosinophilic Esophagitis|
|Study Start Date :||March 2016|
|Estimated Primary Completion Date :||July 2018|
|Estimated Study Completion Date :||December 2018|
Adults with EoE
Adult patients with active eosinophilic esophagitis will under blood collection and esophagus biopsies in order to perform eosinophil isolation and characterization.
Other: Eosinophil isolation and characterization.
Peripheral blood and esophageal biopsies will be obtained from study subjects for further analysis of eosinophils integrin profiles.
- Percentage of eosinophils expressing a4b7 integrin [ Time Frame: 8 weeks ]Eosinophil expression levels of a4b7 integrin will be assessed on peripheral and esophageal eosinophils during active EoE and after treatment-induced remission.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02546219
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||John J Garber, MD||Massachusetts General Hospital|